Navigation Links
Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
Date:7/25/2011

CINCINNATI, July 25, 2011 /PRNewswire/ -- Prasco Laboratories, the Authorized Generics company, announced today it has signed a supply agreement with Shionogi Inc. Under the terms of the agreement, Prasco will market and distribute Mefenamic Acid Capsules, USP 250 mg, the Authorized Generic version of Ponstel®. Prasco intends to begin shipping product immediately in the U.S. under the Prasco label.

"With the introduction of the authorized generic of Shionogi's PONSTEL®, Prasco continues to be the preferred partner for established brand companies to transcend their brands with our Authorized Generics," said Prasco Chief Executive Officer E. Thomas Arington. "We are pleased to have established this relationship with Shionogi Inc., a company that has been providing innovative medicines essential to people's health."

Prasco is the leading Authorized Generics company having brought more Authorized Generics to market than any other company. Prasco Authorized Generics are identical to the NDA brand product. Prasco partners with established brand companies to bring their products to the generics marketplace as Authorized Generics, which offers alternatives for consumers and pharmacists.

Mefenamic Acid Capsules are AB-rated, therapeutically equivalent and substitutable for the brand Ponstel. For additional important information, please click here to see the Full Prescribing Information, INCLUDING BOXED WARNING.

Ponstel® is a registered trademark of Shionogi Inc.

About Prasco Laboratories

Prasco is the privately held healthcare company located in Mason, Ohio, that specializes in Authorized Generics.  Prasco Authorized Generics provide patients with the identical brand drug experience at a price that competes with generics. Prasco Authorized Generics also simplify interactions between pharmacists and consumers because they are identical to branded drugs. Moreover, Prasco Authorized Generics offer brand pharmaceutical companies a strategic lifecycle management solution.

Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant, VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products and cold-chain distribution. For more information, visit www.prasco.com.  

CONTACT:  Kimberly A. Carroll
Advisor to the Chairman,
Corporate Marketing & Communications
k.carroll@prasco.com
513.204.1277
513.550.1473 C
Website:  www.prasco.com


'/>"/>
SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Health, Inc. (Nasdaq: GHDX ) today reported financial results ... 2015. --> --> Revenue was ... million in the fourth quarter of 2014, an increase of 8 ... with the same period in the prior year. ... the fourth quarter of 2015, an increase of 9 percent compared ...
(Date:2/10/2016)... LEXINGTON, Massachusetts , February 10, 2016 --> ... Japan .  --> Japan .  ... Japan .  With submission, Shire continues to ... --> With submission, Shire continues to ... With submission, Shire continues to strengthen ...
(Date:2/10/2016)... and SAN DIEGO , Feb. ... a global leader in viral gene therapy manufacturing, and ... for congestive heart failure and other chronic diseases, have ... scalable manufacturing process and produce cGMP-grade RT-100 (Ad5.hAC6) Drug ... --> --> This ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Ongoing news ... Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer look ... released today illustrates the prevalence and causes of TBI among the aging population, and ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a ... for the fourth quarter and full year ended December 31, 2015 on Monday, February ... and webcast for the investment community following the release at 4:30 PM ET. Investors ...
(Date:2/10/2016)... ... ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves with age, ... Guide to Brain Training" by award-winning author Phyllis Strupp explains how brain ... 16, 2016. A free review copy is available to the media at NetGalley ...
(Date:2/10/2016)... ... 2016 , ... IDEX Health & Science, LLC announces the ... columns combine the strength of traditional stainless steel with the chemical inertness of ... operating at ultra-high pressures of 20,000 psi. The higher operating pressures allow faster ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... The recreational ... cannabis enthusiasts in the state still face a lot of restrictions as to where ... is intended for private, personal use” and that cannabis “may not be consumed openly ...
Breaking Medicine News(10 mins):